ClinicalTrials.gg
CompletedNCT02210780Updated May 7, 2020Results posted

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

A Phase 2 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 42 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-05-07.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
17th of 50
194 · median 75
Started
2014
with 3 others
Phase 2
7 of 50
none open now
Registered
7th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 17th largest by enrollment, is one of 4 that started in 2014, is one of 7 in phase 2, and was the 7th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female adults ages 18 to 64 years with Chronic AD (according to the American Academy of Dermatology Consensus Criteria, [Eichenfeld 2004])that has been present for at least 3 years before the screening visit
  2. Participants with documented recent history (within 6 months before the screening visit) of inadequate response to a sufficient course of outpatient treatment with topical AD medication(s), or for whom topical AD therapies are otherwise inadvisable (e.g., because of side effects or safety risks).
  3. Eczema Area and Severity Index (EASI) score ≥16 at the screening visit and the baseline visit
  4. Investigator's Global Assessment (IGA) score ≥3 (on the 0-4 IGA scale) at the screening and baseline visits
  5. ≥10% body surface area (BSA) of AD involvement at the screening and baseline visits

Key Exclusion Criteria:

  1. Prior treatment with dupilumab (REGN668/ SAR231893)
  2. Patients needing >10 mg of daily prednisone (including equivalent doses of other ) or high dose systemic corticosteroids (≥2 mg/kg) for 14 days or longer during the 16 week treatment period of the study
  3. History of Guillain-Barre syndrome
  4. History of severe allergic reaction to either vaccine or to vaccine components including alum, thimerosal, phenol
  5. Patients with a severe reaction to natural rubber latex products (some packaging components of the vaccines contain rubber latex and may cause a reaction in susceptible individuals)
  6. Treatment with biologics within 4 months of baseline visit
  7. Chronic or acute infection requiring treatment with antibiotics, antivirals, antiparasitics, antifungals within 4 weeks before screening visit or superficial skin infections within 1 week of screening visit

The information listed above is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial and not all inclusion/ exclusion criteria are listed.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Placebo qw

    Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.

    Drug: Placebo

  • Experimental
    Dupilumab 300 mg qw

    Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.

    Drug: Dupilumab

Interventions

  • Administered via subcutaneous injection.

    Also known as: REGN668, SAR231893, Dupixent

  • DrugPlacebo

    An inactive substance containing no medicine administered via subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16

    A positive response was defined as a ≥ 4-fold increase from pre-vaccination at baseline in anti-tetanus immunoglobulin G (IgG) titer for participants with a pre-vaccination tetanus antibody titers ≥ 0.1 IU/ml or a titer of ≥ 0.2 IU/ml for participants with pre-vaccination titers of \<0.1 IU/ml. There was no planned statistical hypothesis testing regarding the difference in immune response between the 2 treatment groups for this study, therefore no formal statistical hypothesis between groups was performed.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With a Positive Response (≥2-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16

    Participants with positive response defined as a ≥2-fold increase from pre-vaccination baseline in anti-tetanus IgG titer for participants with pre-vaccination tetanus antibody titers ≥0.1 IU/ml or a titer of ≥0.2 IU/ml for participants with pre-vaccination titers of \<0.1 IU/ml.

    Time frame: Week 16

  2. Percentage of Participants With a Positive Response (SBA Antibody Titer of ≥8 for Serogroup C) to Menomune Vaccine at Week 16

    A positive response to the Menomune vaccine was a serum bactericidal antibody (SBA) titer of ≥8 for serogroup C.

    Time frame: Week 16

  3. Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16

    IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 16 were counted as non-responders.

    Time frame: Week 16

  4. Percentage of Participants Achieving an Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

    Time frame: Week 16

  5. Percentage of Participants Achieving an Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment use were set to missing and participants with missing EASI score at Week 16 were considered as non-responders.

    Time frame: Week 16

  6. Change From Baseline in Peak Weekly Averaged Pruritis Numerical Rating Scale (NRS) Scores at Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Weekly average obtained in the 7-day period prior to the baseline visit. Values after first rescue medication use were set to missing and missing values were imputed by Last observation carried forward (LOCF).

    Time frame: Baseline to Week 16

  7. Change From Baseline in Body Surface Area (BSA) Affected by AD at Week 16

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  8. Change From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations and Lichenification) at Week 16

    Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). Values after first rescue treatment were set to missing. Analysis was completed using MMRM model which includes treatment, randomization strata, visit, baseline value, treatment-by-visit interaction, and baseline-by-visit interaction as covariates. These results are observed results without imputation.

    Time frame: Baseline to Week 16

  9. Changes From Baseline in GISS Cumulative Score to Week 16

    Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  10. Change in Patient Oriented Eczema Measure (POEM) Score From Baseline to Week 16

    The POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

07

Results

Posted May 7, 2020

Participant flow

The study was conducted at approximately 50 study sites in United States (US) between 05 August 2014 and 15 September 2015. A total of 243 participants were screened in the study.

Participant flow — Overall Study
MilestonePlacebo qwDupilumab 300 mg qw
Started9797
Completed9289
Not completed58
Withdrew: Adverse event05
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject11
Withdrew: Physician decision10
Withdrew: Protocol violation10
Withdrew: Other than specified above01

Outcome measures

PrimaryPercentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16

A positive response was defined as a ≥ 4-fold increase from pre-vaccination at baseline in anti-tetanus immunoglobulin G (IgG) titer for participants with a pre-vaccination tetanus antibody titers ≥ 0.1 IU/ml or a titer of ≥ 0.2 IU/ml for participants with pre-vaccination titers of \<0.1 IU/ml. There was no planned statistical hypothesis testing regarding the difference in immune response between the 2 treatment groups for this study, therefore no formal statistical hypothesis between groups was performed.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16
Percentage of participantsPlacebo qwDupilumab 300 mg qw
Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 1683.783.3
SecondaryPercentage of Participants With a Positive Response (≥2-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16

Participants with positive response defined as a ≥2-fold increase from pre-vaccination baseline in anti-tetanus IgG titer for participants with pre-vaccination tetanus antibody titers ≥0.1 IU/ml or a titer of ≥0.2 IU/ml for participants with pre-vaccination titers of \<0.1 IU/ml.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With a Positive Response (≥2-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16
Percentage of participantsPlacebo qwDupilumab 300 mg qw
Percentage of Participants With a Positive Response (≥2-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 1694.695.6
SecondaryPercentage of Participants With a Positive Response (SBA Antibody Titer of ≥8 for Serogroup C) to Menomune Vaccine at Week 16

A positive response to the Menomune vaccine was a serum bactericidal antibody (SBA) titer of ≥8 for serogroup C.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With a Positive Response (SBA Antibody Titer of ≥8 for Serogroup C) to Menomune Vaccine at Week 16
Percentage of participantsPlacebo qwDupilumab 300 mg qw
Percentage of Participants With a Positive Response (SBA Antibody Titer of ≥8 for Serogroup C) to Menomune Vaccine at Week 1687.086.7
SecondaryPercentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16

IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16
Percentage of participantsPlacebo qwDupilumab 300 mg qw
Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 1610.344.3
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: 34.0 · 90% CI 24.29 to 43.75Dupilumab 300 mg qw vs. Placebo qw
SecondaryPercentage of Participants Achieving an Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16
Percentage of participantsPlacebo qwDupilumab 300 mg qw
Percentage of Participants Achieving an Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 1632.072.2
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: 40.2 · 90% CI 29.40 to 51.01Dupilumab 300 mg qw vs. Placebo qw
SecondaryPercentage of Participants Achieving an Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment use were set to missing and participants with missing EASI score at Week 16 were considered as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16
Percentage of participantsPlacebo qwDupilumab 300 mg qw
Percentage of Participants Achieving an Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 1619.653.6
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: 34.0 · 90% CI 23.38 to 44.66Dupilumab 300 mg qw vs. Placebo qw
SecondaryChange From Baseline in Peak Weekly Averaged Pruritis Numerical Rating Scale (NRS) Scores at Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Weekly average obtained in the 7-day period prior to the baseline visit. Values after first rescue medication use were set to missing and missing values were imputed by Last observation carried forward (LOCF).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Peak Weekly Averaged Pruritis Numerical Rating Scale (NRS) Scores at Week 16
Units on a scalePlacebo qwDupilumab 300 mg qw
Change From Baseline in Peak Weekly Averaged Pruritis Numerical Rating Scale (NRS) Scores at Week 16-2.11 ± 0.259-4.24 ± 0.250
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg qw · ANCOVA · p = <0.0001 · Ls mean difference: -2.13 · 90% CI -2.72 to -1.55Dupilumab 300 mg qw vs. Placebo qw
SecondaryChange From Baseline in Body Surface Area (BSA) Affected by AD at Week 16

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Percentage of BSA
Change From Baseline in Body Surface Area (BSA) Affected by AD at Week 16
Percentage of BSAPlacebo qwDupilumab 300 mg qw
Change From Baseline in Body Surface Area (BSA) Affected by AD at Week 16-11.0 ± 2.11-28.7 ± 2.00
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg qw · ANCOVA · p = <0.0001 · Ls mean difference: -17.8 · 90% CI -22.5 to -13.1Dupilumab 300 mg qw vs. Placebo qw
SecondaryChange From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations and Lichenification) at Week 16

Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). Values after first rescue treatment were set to missing. Analysis was completed using MMRM model which includes treatment, randomization strata, visit, baseline value, treatment-by-visit interaction, and baseline-by-visit interaction as covariates. These results are observed results without imputation.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations and Lichenification) at Week 16
Units on a scalePlacebo qwDupilumab 300 mg qw
Erythema-0.4 ± 0.08-0.9 ± 0.08
Infiltration/Papulation-0.4 ± 0.08-1.1 ± 0.08
Excoriations-0.5 ± 0.09-1.2 ± 0.08
Lichenification-0.4 ± 0.09-1.0 ± 0.09
SecondaryChanges From Baseline in GISS Cumulative Score to Week 16

Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Units on a scale
Changes From Baseline in GISS Cumulative Score to Week 16
Units on a scalePlacebo qwDupilumab 300 mg qw
Changes From Baseline in GISS Cumulative Score to Week 16-1.7 ± 0.28-4.1 ± 0.28
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg qw · ANCOVA · p = <0.0001 · Ls mean difference: -2.4 · 90% CI -3.0 to -1.7Dupilumab 300 mg qw vs. Placebo qw
SecondaryChange in Patient Oriented Eczema Measure (POEM) Score From Baseline to Week 16

The POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Units on a Scale
Change in Patient Oriented Eczema Measure (POEM) Score From Baseline to Week 16
Units on a ScalePlacebo qwDupilumab 300 mg qw
Change in Patient Oriented Eczema Measure (POEM) Score From Baseline to Week 16-4.8 ± 0.72-13.1 ± 0.70
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg qw · ANCOVA · p = <0.0001 · Ls mean difference: -8.3 · 90% CI -9.9 to -6.6Dupilumab 300 mg qw vs. Placebo qw

Adverse events

Collected over Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 32) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo qw0/97 (0%)0/97 (0%)29/97 (29.9%)
Dupilumab 300 mg qw0/97 (0%)3/97 (3.1%)30/97 (30.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo qwDupilumab 300 mg qw
Serum sickness-like reactionImmune system disorders0/971/97
Mycosis fungoides stage ivNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/971/97
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/971/97
Most frequent other events
Most frequent other events
EventPlacebo qwDupilumab 300 mg qw
Upper respiratory tract infectionInfections and infestations14/9711/97
Dermatitis atopicSkin and subcutaneous tissue disorders11/971/97
ConjunctivitisInfections and infestations0/978/97
Injection site reactionGeneral disorders0/975/97
NasopharyngitisInfections and infestations5/974/97
HeadacheNervous system disorders3/975/97

Baseline characteristics

The safety analysis set (SAF) included all randomized participants who received any study drug, and was analyzed as treated. Any participant given at least 1 dupilumab injection was assigned to the dupilumab group. The safety analysis was based on the SAF.

Age, Continuous
Age, Continuous(years)Placebo qwDupilumab 300 mg qwTotal
Mean39.9 ± 14.0439.2 ± 13.5539.6 ± 13.77
Sex: Female, Male
Sex: Female, Male(Participants)Placebo qwDupilumab 300 mg qwTotal
Female514899
Male464995
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo qwDupilumab 300 mg qwTotal
Hispanic or Latino131528
Not Hispanic or Latino8481165
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo qwDupilumab 300 mg qwTotal
White6760127
Black or African American172340
Asian111223
American Indian or Alaska Native011
Other213
Anti-tetanus Immunoglobulin G (IgG) Titer
Anti-tetanus Immunoglobulin G (IgG) Titer(IU/mL)Placebo qwDupilumab 300 mg qwTotal
Mean1.74 ± 1.9081.51 ± 1.3281.62 ± 1.644
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(units on a scale)Placebo qwDupilumab 300 mg qwTotal
Mean31.23 ± 13.77129.04 ± 13.08530.14 ± 13.442
Investigator Global Assessment (IGA) Score
Investigator Global Assessment (IGA) Score(units on a scale)Placebo qwDupilumab 300 mg qwTotal
Mean3.4 ± 0.493.4 ± 0.493.4 ± 0.49
Weekly Peak Pruritus Numeric Rating Scale (NRS)
Weekly Peak Pruritus Numeric Rating Scale (NRS)(Units on a Scale)Placebo qwDupilumab 300 mg qwTotal
Mean7.3 ± 2.197.4 ± 2.207.3 ± 2.19

2 further baseline measures are reported on the registry.

08

Study locations

42 sites
  • Birmingham, Alabama, United States
  • Fort Smith, Arkansas, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Mission Viejo, California, United States
  • Rolling Hills Estates, California, United States
  • San Diego, California, United States
  • Santa Monica, California, United States
  • Denver, Colorado, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Tampa, Florida, United States
  • Macon, Georgia, United States
  • Chicago, Illinois, United States
  • Maywood, Illinois, United States
  • West Dundee, Illinois, United States
  • Indianapolis, Indiana, United States
  • Plainfield, Indiana, United States
  • Overland Park, Kansas, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Troy, Michigan, United States
  • Saint Louis, Missouri, United States
  • Hackensack, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Buffalo, New York, United States
  • Forest Hills, New York, United States
  • New York, New York, United States
  • Cleveland, Ohio, United States
  • Norman, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Medford, Oregon, United States
  • Portland, Oregon, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Greer, South Carolina, United States
  • Arlington, Texas, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • Webster, Texas, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Sep 2015, 13 months.

Results were first posted in May 2020, 4 years 7 months after primary completion. A results delay was requested in Feb 2017.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 13 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2014
First posted
Aug 7, 2014
StartActual
Aug 5, 2014
Primary completionActual
Sep 15, 2015
CompletionActual
Sep 15, 2015
Results delay requested
Feb 7, 2017
Results first posted
May 7, 2020
Last update
May 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02210780
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Aug 7, 2014
Start date
Aug 5, 2014
Primary completion
Sep 15, 2015
Completion
Sep 15, 2015
Results posted
May 7, 2020
Last update
May 7, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion